IFITM Proteins Restrict Antibody-Dependent Enhancement of Dengue Virus Infection by Chan, Ying Kai et al.
IFITM Proteins Restrict Antibody-Dependent
Enhancement of Dengue Virus Infection
Ying Kai Chan*, I-Chueh Huang, Michael Farzan*
New England Primate Research Center, Department of Microbiology and Immunobiology, Harvard Medical School, Southborough, Massachusetts, United States of
America
Abstract
Interferon-inducible transmembrane (IFITM) proteins restrict the entry processes of several pathogenic viruses, including the
flaviviruses West Nile virus and dengue virus (DENV). DENV infects cells directly or via antibody-dependent enhancement
(ADE) in Fc-receptor-bearing cells, a process thought to contribute to severe disease in a secondary infection. Here we
investigated whether ADE-mediated DENV infection bypasses IFITM-mediated restriction or whether IFITM proteins can be
protective in a secondary infection. We observed that IFITM proteins restricted ADE-mediated and direct infection with
comparable efficiencies in a myelogenous leukemia cell line. Our data suggest that IFITM proteins can contribute to control
of secondary DENV infections.
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Introduction
The four serotypes of dengue virus (DENV1–4) are responsible
for approximately 50 to 100 million infections annually, and 2.5
billion people are at risk of infection, making DENV the most
widespread arboviral disease [1,2]. Most symptomatic DENV
infections present as a debilitating, febrile disease known as dengue
fever (DF), but serious cases can progress to dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS). These can be fatal
if patients do not receive fluid replacement. Currently, there are
no approved therapies for DENV infections.
Clinical and autopsy studies indicate that cells of the
mononuclear phagocyte lineage, including monocytes/macro-
phages and dendritic cells, are primary targets of DENV in vivo
[3]. In addition, epidemiological studies show that DHF/DSS
often occurs in patients with secondary heterotypic DENV
infections or in infants with maternally transferred dengue
immunity [4,5]. Antibody-dependent enhancement (ADE) is
thought to be a major contributor to severe disease following
secondary infection [4]. In a secondary infection with a
heterologous serotype, the virus forms immune complexes with
pre-existing sub-neutralizing antibodies and bind to Fc-receptor-
bearing cells, leading to increased infection and viral replication
[5]. The cell biology of ADE is not fully understood, but some
proposed mechanisms include: increased virus attachment to the
cell surface, increased efficiency in post-attachment steps due to
Fc-receptor-mediated signaling, delivery of antibody-virus com-
plexes to more favorable locations in the endocytic compartment,
and direct alterations in the fusion process (reviewed in [6,7]).
We have recently shown that interferon-inducible transmem-
brane (IFITM) proteins restrict replication of multiple viruses,
including influenza A (IAV), SARS coronavirus, filoviruses (Ebola
and Marburg viruses) and flaviviruses (including dengue and West
Nile viruses), whereas vesicular stomatitis virus is less efficiently
restricted [8,9]. Other groups have also demonstrated that IFITM
proteins restrict HIV-1 [10,11]. In addition, IFITM-mediated
restriction of flaviviruses has been confirmed in two subsequent
studies [11,12]. The IFITM proteins are relatively small (,130
amino acids) and share a common topology, with two conserved
transmembrane domains, a short highly conserved cytoplasmic
region, and luminal amino- and carboxy-termini [13]. In humans,
IFITM1, 2, and 3 are expressed in a wide range of tissues, while
IFITM5 expression is limited to bone [14]. As their names suggest,
IFITM proteins are strongly upregulated by type I and II
interferons [8,9,15], and most cells express basal levels of one or
more of these proteins [16]. Currently, IFITM proteins are the
only known mediators of innate immunity that inhibit viral
infection by blocking viral entry [17].
We have demonstrated that IFITM1, 2, and 3 restrict entry
mediated by IAV, SARS coronavirus and filovirus entry proteins
in vitro, and abrogate infection by three flavivirus virus-like particles
(VLPs), suggesting that IFITM proteins also restrict flavivirus
infections by blocking virus entry [8]. In agreement with this, Jiang
et al. [12] have shown that IFITM proteins restrict infection by
flavivirus VLPs, but do not inhibit replication of flavivirus
replicons. In contrast, IFITMs do not inhibit the entry processes
of amphotropic mouse leukemia virus (MLV), Machupo virus
(MACV), Lassa virus (LASV) or lymphocytic choriomeningitis
virus (LCMV) [8].
Currently it is not clear what distinguishes the entry
mechanisms of IFITM-restricted and IFITM-insensitive viruses
or how IFITM proteins suppress viral entry. In addition, IFITM-
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the plasma membrane, suggesting that the site or mechanism of
viral entry can affect the sensitivity to IFITM-mediated restriction
[9]. Given the potential importance of ADE to severe dengue
disease and the lack of full understanding of the biology of ADE,
an attractive hypothesis is that, unlike direct DENV infection,
ADE-mediated DENV infection bypasses IFITM-mediated re-
striction, thereby increasing viral replication and disease severity in
a secondary infection.
In this study, we sought to determine if ADE could bypass
IFITM-mediated restriction, or, alternatively, if IFITM proteins
could contribute to the control of DENV in secondary infections as
well. Previous studies of IFITM-mediated restriction of flaviviruses
used cell lines lacking Fc receptors [8,11,12]. Here, we infected
human myelogenous leukemia K562 cells, which bear FccRIIa,
with DENV (direct infection) or antibody-opsonized DENV
(ADE-mediated infection). We show that IFITM proteins are able
to restrict both direct and ADE-mediated infection, and that both
infection modes appear equally sensitive to IFITM-mediated
restriction.
Results and Discussion
We first investigated the basal and interferon-induced expres-
sion of IFITM proteins in K562 cells, using an antibody that
recognizes IFITM1 alone, or one that recognizes both IFITM2
and IFITM3 [8,9]. Western blot analysis showed that resting
K562 cells express a basal level of IFITM1 and IFITM2 and/or 3,
and that treatment with human IFN-a for 48 h strongly
upregulated expression of both IFITM1 and IFITM2/3 (Fig. 1A).
Figure 1. IFITM proteins restrict both direct and ADE-mediated DENV infection of K562 cells. (A) K562 cells were treated with the
indicated concentrations of human interferon-a or mock treated, and lysed for Western blot analysis 48 h later, using an antibody that recognizes
IFITM1 alone, or one that recognizes both IFITM2 and IFITM3. (B) K562 cells were stably transduced to express human IFITM1, 2, or 3 or with the
control vector pQCXIP. IFITM protein expression was measured by Western blot using an anti-c-myc antibody. (C) Stably transduced K562 cells
characterized in panel B were infected with an MLV-based retrovirus expressing EGFP and pseudotyped with MACV or IAV H5 entry proteins, as
previously described [9]. Infection was determined by flow cytometry, and normalized to K562 cells transduced with vector alone. (D) K562 cells
characterized in panel B were infected with infectious DENV2 NGC strain (labeled ‘‘DENV2’’ for virus only) at the indicated MOI, or the same amount of
infectious DENV2 pre-opsonized with enhancing titers of antibodies against DENV structural proteins prM or E (‘‘+2H2’’ and ‘‘+4G2’’ respectively)
[8,21]. Cells were washed after 1.5 h and incubated for ,24 h. Intracellular staining of DENV antigen was performed with a DyLight-649-conjugated
antibody against prM and infection was determined by flow cytometry. Experiment is representative of three with similar results. (E) An experiment
similar to that shown in panel D was performed except that infection was assayed by measuring viral loads in the supernatant by plaque assays using
BHK cells. (F) An experiment similar to that in panel D was performed, except that J774A.1 murine macrophage cells were stably transduced to
express murine orthologs of IFITM1, 2, or 3 or with the control vector pQCXIP. Stably transduced cells were infected with infectious DENV2 NGC strain
at ,MOI 5 and incubated for ,2 days before harvesting for flow cytometry. Error bars indicate standard error. Single and double asterisks indicate
statistically significant (P,0.05 and P,0.005, respectively) differences between IFITM protein expressing and control cells for corresponding infection
conditions.
doi:10.1371/journal.pone.0034508.g001
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transduced K562 cells to stably express myc-tagged IFITM1, 2 or
3, or with vector alone, and selected transduced cells with
puromycin. Western blot analysis using an antibody against c-myc
showed robust expression of each IFITM protein (Fig. 1B). To
verify their activities, we infected transduced cells with viral
pseudoparticles that contain an MLV genome encoding the
enhanced green fluorescence protein (EGFP), and pseudotyped
with entry proteins of IAV (A/Thailand/2(SP-33)/2004 (H5N1))
or MACV [18,19]. Pseudovirus infection was measured two days
later by flow cytometry. As expected, overexpression of IFITM1, 2
or 3 potently restricted infection by MLV-EGFP virus pseudo-
typed with IAV but not MACV entry proteins (Fig. 1C).
We next infected these cells with infectious DENV2 New
Guinea C strain (NGC) propagated in mosquito C6/36 cells.
DENV2 was incubated in media alone, or with enhancing titers of
monoclonal antibodies against dengue prM or envelope (E). We
used two commercially available antibodies, 2H2 and 4G2, which
bind dengue virus structural proteins prM and E respectively.
Anti-prM antibodies opsonize virions that are not fully mature
while antibodies against E can opsonize most virions (reviewed in
[20]). As previously described [21], dengue virions were incubated
with each antibody or with media alone, and subsequently
incubated with K562 cells. Previous studies have shown that
intracellular staining of DENV antigen less than 43 h post-
infection of K562 cells indicates a single round of infection [22].
Accordingly, to evaluate viral entry, we assessed productive
infection by intracellular prM-staining 24 h post-infection [23].
As expected, with direct (antibody-independent) infection at a
multiplicity of infection (MOI) 1, expression of IFITM1, 2, or 3
potently inhibited infection by ,80% when compared to vector-
transduced cells. With ADE-mediated infection at MOI 1, baseline
infectivity increased roughly three-fold indicating successful ADE,
but expression of IFITM1, 2 or 3 continued to potently inhibit
infection by ,70–90% (n=3 or 4 per condition; P,0.05).
Similarly, at MOI 10, we observed less efficient restriction, but
comparable restriction levels in direct and ADE-mediated
infection (Fig. 1D). Consistent with our previous studies, IFITM2
restricted DENV infection less efficiently than either IFITM1 or
IFITM3 [8]. We further quantified viral loads in the supernatant
by standard plaque assays with BHK cells [21]. Again,
overexpression of IFITM1 or IFITM3 effectively restricted
ADE-mediated infection, and suppressed viral production by
more than 10-fold (Fig. 1E; n=3; P,0.05). Finally, we verified the
generality of our observations by confirming them in J774A.1
murine macrophages [24] stably expressing murine orthologs of
IFITM1, 2 or 3 (Fig. 1F; n=4; asterisks indicate P,0.05). We
conclude that IFITM1, 2 or 3 can restrict ADE-mediated DENV
infection of K562 cells.
We subsequently investigated whether endogenous IFITM
proteins contributed to DENV restriction. We stably transduced
K562 cells to express previously characterized shRNAs against
IFITM1, 2, or 3 [8,9], or with a control non-targeting shRNA
(scrambled), and selected transduced cells with puromycin.
IFITM1 expression was nearly undetectable in cells expressing
shRNA targeting IFITM1, whereas IFITM2 and 3 levels were
unaffected. shRNA targeting IFITM2 reduced IFITM2/3 expres-
sion slightly, while shRNA targeting IFITM3 substantially reduced
IFITM2/3 expression (Fig. 2A). As we have previously observed
[9], IFITM1 depletion increased infection by IAV pseudoviruses
by almost 2-fold, whereas little or no increase in infection was
observed with shRNA targeting IFITM2 or IFITM3 (Fig. 2B).
Similarly, with DENV2 infection at MOI 1, knockdown of
IFITM1 roughly doubled infection rates with both direct and
ADE-mediated infections (Fig. 2C; n=3 or 4; P,0.05). This
increase was less pronounced at a higher MOI of 10, but remained
statistically significant. These data show that endogenous IFITM1
in K562 cells restricts ADE-mediated DENV infection.
Figs. 1 and 2 show that ADE cannot bypass IFITM-mediated
restriction, but leave open the possibility that ADE-mediated
infection is quantitatively less sensitive to restriction than direct
infection. To determine if IFITM proteins restrict ADE-mediated
infection to the same extent as direct infection, we identified in
pilot studies virus titers for direct and ADE-mediated infection that
resulted in comparable infectivity, and used these titers to
investigate the effect of IFITM overexpression or IFITM1
depletion as in Figs. 1D and 2C. When IFITM1, 2 or 3 were
over-expressed in K562 cells under these conditions, nearly
identical restriction was observed in direct and ADE-mediated
infection (Fig. 3A). Similarly when IFITM1 was depleted in the
same cells, a comparable increase in infection was observed
(Fig. 3B). We conclude that IFITM proteins restrict ADE-
mediated infection and direct infection with similar efficiencies.
We have previously shown that IFITM-mediated restriction
depends on the site or mechanism of viral entry [9]. This finding
raised a key question: can ADE facilitate bypass of this restriction,
or, instead, can IFITM proteins contribute to control of a
secondary infection, including those resulting in DHF/DSS? Our
data show clearly that in a human myelogenous leukemia cell line
widely used in the study of ADE [22,25,26], IFITM proteins
restrict ADE-mediated infection as efficiently as direct infection.
Therefore, we find no evidence supporting the hypothesis that
ADE-mediated DENV infection bypasses or is less sensitive to
IFITM-mediated restriction. It is formally possible that differences
in cell types, antibody properties, or viral strains could alter the
sensitivity of ADE-mediated infection to IFITM restriction.
However we show that our observations are consistent across
two different cell lines from two species expressing their respective
IFITM orthologs. In addition, it has been suggested that patients
with DHF exhibit lower IFN-a levels than patients with DF
(reviewed in [27]), which may lead to reduced IFITM-induction.
In vivo studies may be necessary to clarify these possibilities.
Nonetheless, our observation suggests that therapeutic strategies
that specifically induce IFITM activity could control both primary
and secondary dengue virus infections.
To date, the mechanisms of IFITM-mediated restriction remain
elusive. We have previously demonstrated that IFITM proteins do
not interfere with virion access to acidic cellular compartments [9].
Furthermore, inducing viral fusion at the plasma membrane
bypasses IFITM-mediated restriction [9], supporting a mechanism
which operates within the endocytic pathway. Our work in this
study shows that IFITM proteins restrict ADE-mediated DENV
infection as efficiently as direct infection, but does not distinguish
between the possible mechanisms of ADE, including alterations in
viral attachment, endocytosis and/or fusion. However, the similar
sensitivity of direct and ADE-mediated infection to IFITM
restriction indicates that these infection modes share common
features that render them both sensitive to IFITM proteins.
Materials and Methods
Cells and plasmids
Human embryonic kidney 293T cells and murine macrophage
J774A.1 cells were grown in Dulbecco’s minimal essential medium
(DMEM; Invitrogen) and human myelogenous leukemia K562
cells were grown in Roswell Park Memorial Institute (RPMI) 1640
medium (Invitrogen). Media were supplemented with 10% fetal
bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin.
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fense and Emerging Infectious Research Resources Depository,
NIAID, NIH and used to stimulate K562 cells at indicated
concentrations in growth media for 48 h. Plasmids encoding c-
myc-tagged IFITM proteins in pQCXIP vector and plasmids
encoding control shRNA or shRNA targeting IFITMs in pRS
vector have been described [9]. Transduced K562 or J774A.1 cells
were selected by supplementing media with 3 or 4 mg/ml
puromycin(Invitrogen), respectively.
Western blots
Cells were lysed with 1% NP-40 (Thermo Scientific) and
Western blot analysis was performed as previously described [9].
C-myc-tagged IFITM proteins were detected by a murine
monoclonal anti-c-myc antibody (9E10, Santa Cruz Biotechnol-
ogy). Endogenous IFITM protein expression was detected by
polyclonal rabbit anti-IFITM1 (FL-125, Santa Cruz Biotechnol-
ogy) or rabbit anti-IFITM2 (12769-1-AP, Proteintech Group,
cross reacts with IFITM3 protein). Anti-tubulin antibodies (Sigma)
were used as a loading control.
Pseudotyped murine leukemia viruses (MLVs) for
transduction and infection assays
Viral entry proteins, plasmids and procedures for generating
pseudotyped MLV-EGFP have been described [9]. Entry proteins
used are IAV HA proteins from A/Thailand/2(SP-33)/2004(H5N1)
and glycoprotein (GP) from Machupo virus Carvallo. Similarly,
transduction of K562 or J774A.1 cells and MLV-EGFP pseudovirus
infection procedures have been described [9]. Relative infectivity
was calculated by normalizing against infectivity in control cells.
Figure 2. Endogenous IFITM1 restricts both direct and ADE-mediated DENV infection of K562 cells. (A) K562 cells were stably
transduced to express shRNA targeting IFITM1, 2, or 3 or non-targeting control shRNA (scrambled). IFITM protein expression was measured by
Western blot, as in Fig. 1A. (B) shRNA-transduced K562 cells characterized in panel A were infected with the indicated pseudoviruses as described in
Fig. 1C. (C) shRNA-transduced K562 cells characterized in panel A were infected with infectious DENV2 NGC strain as described in Fig. 1D. Error bars
indicate standard error. Single and double asterisks indicate statistically significant (P,0.05 and P,0.005, respectively) differences between cells
expressing IFITM1 and control shRNA for corresponding infection conditions. Experiment is representative of three with similar results.
doi:10.1371/journal.pone.0034508.g002
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DENV2 New Guinea C strain (NGC) was propagated in Aedes
albopictus C6/36 cells, clarified by centrifugation and stored at
280uC. Virus titers were measured by standard plaque assays on
BHK cells [21]. Direct and ADE-mediated infections were
performed based on a published protocol with minor modifica-
tions [21]. Murine 2H2 and 4G2 antibodies were purchased from
Millipore. Briefly, DENV2 was incubated in RPMI containing 2%
FBS with or without enhancing titers of 2H2 (20 ng for MOI 1
and 200 ng for MOI 10) or 4G2 antibodies (,20 ng for both MOI
1 and 10) in a total volume of 250 ml for 30 min at 37uC. 2610
5
K562 cells in a similar volume of media in 24-well plates were then
infected similarly to pseudovirus infection procedures. After
incubation for 1.5 h at 37uC, cells were then washed in DPBS
and incubated for ,24 h before harvesting cells for flow cytometry
or supernatant for plaque assay. Cells were assayed for productive
infection by intracellular prM staining [23] and analyzed by flow
cytometry. The supernatant was clarified by centrifugation, frozen
at 280uC, before plaque assays were performed with BHK cells.
The infection protocol was slightly modified for adherent J774A.1
cells. 2610
5 cells were seeded overnight in 12-well plates and
infected with a similar total volume (500 m l) of virus or virus-
antibody complex in DMEM containing 2% FBS the next day.
After infection and washing, cells were incubated for ,2 days
before harvesting for flow cytometry. Enhancing titers of 2H2
were based on a previous study [21] while enhancing titers of 4G2
were empirically determined in a pilot experiment using serial 10-
fold dilutions of the antibody complexed with DENV2 at MOI 1
or MOI 10. The dilution that gave the best enhancement in
infection of K562 cells was subsequently used in all experiments.
All statistical analysis was performed using a one-tailed Student’s t
test. P,0.05 was considered statistically significant.
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